ANTX vs SEPN
ANTX: AN2 Therapeutics leverages a proprietary boron chemistry platform to develop small-molecule drugs for neglected infectious diseases, blood cancers, and other high-unmet-need conditions. SEPN: An early-stage biotech company developing cell receptor-targeted therapeutics for inflammation, metabolism, and other diseases through its proprietary chemistry platform.
Side-by-side fundamentals
| Metric | ANTX | SEPN | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $4.89 | $34.20 | |
| Market cap as of 2026-07-23 | $176M | $1.5B | |
| Net margin as of 2026-07-23 | n/a | -49.9% | |
| Operating margin as of 2026-07-23 | n/a | -77.1% | |
| ROE as of 2026-07-23 | -52.3% | -9.4% | SEPN higher |
| ROA as of 2026-07-23 | -47.3% | -6.6% | SEPN higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +11790.1% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +1644.5% | |
| Beta as of 2026-07-23 | -1.00 | 0.62 | |
| 1-year return as of 2026-07-22 close | +342.5% | +173.6% | ANTX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.